All articles tagged with #tumor remission
A redesigned CD40 antibody drug, tested in a small clinical trial, has shown promising results by shrinking or eliminating tumors in some patients with metastatic cancers, with fewer side effects than previous versions, and appears to activate a systemic immune response.
A modified CD40 agonist antibody, 2141-V11, shows promising results in a Phase I trial by shrinking or eliminating tumors in patients with aggressive cancers, with minimal side effects, and induces systemic immune responses, including in tumors not directly injected. The drug enhances immune activity within tumors and is being further studied in larger trials for various cancers.